[{"id":"7d68e07b-11ee-4609-9459-b4a8e162aed2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454165","created_at":"2021-01-18T17:01:54.498Z","updated_at":"2024-07-02T16:35:58.227Z","phase":"Phase 1","brief_title":"A Study of BNC105P Combined With Ibrutinib","source_id_and_acronym":"NCT03454165","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" BCL2 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["BCL2 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • BNC105"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 01/14/2021","primary_completion_date":" 01/14/2021","study_txt":" Completion: 01/14/2021","study_completion_date":" 01/14/2021","last_update_posted":"2023-01-04"}]